Quarterly report pursuant to Section 13 or 15(d)

Organization, Description of Business, Basis of Presentation, Reclassifications, Reverse Stock Split, Business Disposals, and Advance (Details)

v3.20.2
Organization, Description of Business, Basis of Presentation, Reclassifications, Reverse Stock Split, Business Disposals, and Advance (Details)
3 Months Ended 6 Months Ended
Oct. 24, 2019
USD ($)
Jul. 15, 2019
USD ($)
Jul. 05, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2019
USD ($)
Dec. 31, 2019
USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Reverse stock split, conversion ratio 30              
Excess consideration note matured amount $ 6,000,000.0              
Interest paid       $ 0 $ 1,063,000 $ 0 $ 2,173,000  
Earn-Out from siParadigm, current portion       740,000   740,000   $ 747,000
Earn-Out from siParadigm, less current portion       48,000   48,000   356,000
BioPharma Disposal                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Gross consideration $ 153,000 $ 23,500,000            
Closing adjustments   2,000,000.0            
Promissory note receivable   7,700,000            
Cash received from transaction   $ 2,300,000            
Interest rate 6.00%              
Interest paid $ 24,000              
Net worth adjustment 775,000              
Security for indemnification obligations $ 735,000              
PFG | Secured Debt                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Term note, principal balance       6,000,000.0   6,000,000.0    
siParadigm                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Due to affiliate, current       536,000   536,000   566,000
Due to affiliate, noncurrent       72,000   72,000   $ 252,000
Clinical Agreement                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Cash consideration received, total     $ 747,000          
Cash consideration received for equipment     45,000          
Payments on Advance from NovellusDx, Ltd.     1,000,000.0          
Supplier invoices paid directly to related party     177,000          
Adjustment     11,000          
Transaction costs     $ 110,000          
Term of contract     24 months          
Period of service     12 months          
Non-compete term     3 years          
Transition Services Agreement | BioPharma Disposal                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Related party shares services       97,000   199,000    
Reimbursement of Salaries and Benefits | BioPharma Disposal                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Related party shares services       $ 48,000   $ 150,000    
Discontinuing Operations | Convertible Note                
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]                
Interest expense, debt         $ 657,000   $ 1,400,000